SEC Form 4 · accession 0001437749-15-012784
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Edwardson
Officer — Chief Operations Officer
Period of report
Jun 19, 2015
Accepted (ET)
Jun 23, 2015 · 8:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 19, 2015 | A | 7,812 | $0.00 | A | 44,332 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1,F2 | $14.12 | Jun 19, 2015 | A | 15,400 | A | — | Jun 19, 2025 | Ordinary Shares | 15,400 | 15,400 | D |
Explanation of responses
- F1Option granted under Issuer's 2013 Share Incentive Plan.
- F2Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2016 through January 1, 2019.